APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Financial Statements and Exhibits
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated March 18, 2019. |
Aptevo Therapeutics Inc. Exhibit
EX-99.1 2 apvo-ex991_40.htm EX-99.1 apvo-ex991_40.htm Exhibit 99.1 For Immediate Release APTEVO THERAPEUTICS REPORTS 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Achieves Record Annual IXINITY® Net Revenue of $23.1 Million Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Receives Authorization to Commence Dosing in Phase 1 Clinical Trial of APVO210; Dosing Scheduled to Begin March 2019 Progresses Novel 4-1BB/5T4 Bispecific Antibody ALG.APV-527 Towards CTA Filing in Q4 2019 SEATTLE,…
To view the full exhibit click here
About APTEVO THERAPEUTICS INC. (NASDAQ:APVO)
Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).
